Certain patients with germ cell cancer should receive life-long follow-up
the ONA take:
Patients with disseminated germ cell cancer who survive after more than one line of treatment have an increased risk for late toxicity and death, and therefore should be candidates for life-long follow-up care, a new study published online ahead of print in the Journal of Clinical Oncology has shown.
For the study, researchers identified 268 patients with germ cell cancer who received more than one line of treatment for disseminated disease from the Danish Testicular Cancer database to evaluate late toxicity and survival.
Results showed that just more than half of patients died from germ cell cancer. The remaining patients had an increased risk for developing a second cancer, major cardiovascular disease, pulmonary disease, gastrointestinal disease, renal impairment, neurologic disorders, and death from other causes compared with patients who only underwent orchiectomy.
Researchers found that increasing age may contribute to treatment failure after second-line treatment in these patients.
Patients with disseminated germ cell cancer who survive after more than one line of treatment have an increased risk for late toxicity and death.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|